Title |
Annual International Primary CNS Lymphoma Collaborative Group Meeting
|
Institution |
MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA
|
Principal Investigator |
BATCHELOR, TRACY
|
NCI Program Director |
Song
|
Cancer Activity |
Clinical Oncology
|
Division |
DCTD
|
Funded Amount |
$5,000
|
Project Dates |
09/01/2006 - 11/30/2017
|
Fiscal Year |
2017
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Aging (100.0%)
Cancer (100.0%)
|
Central Nervous System - Not Including Brain (50.0%)
Non Hodgkins Lymphoma (50.0%)
|
Research Type |
Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
Resources and Infrastructure Related to Treatment and the Prevention of Recurrence
|
Abstract |
"Project Summary Primary central nervous system lymphoma (PCNSL) is an extranodal variant of non-Hodgkin lymphoma (NHL) that is confined to the nervous system. The diagnostic and therapeutic approaches to PCNSL are different from those that are applied to other forms of NHL or to other brain cancers. The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) consists of specialists from multiple countries and disciplines dedicated to the study of PCNSL. The IPCG holds an annual scientific conference at the American Society of Hematology meeting in which various research topics related to PCNSL are discussed. An international expert on the topic under discussion is selected each year by an executive committee to chair the scientific conference. These meetings have led to multiple collaborative projects that have positively impacted the field and that have been published in the peer-reviewed literature. The annual IPCG meeting is a critical forum for generating new ideas and approaches to this unique form of brain cancer and lymphoma. The 2016 conference topic is Management of Elderly Patients with PCNSL. The median age at diagnosis of PCNSL is 65 but many clinical trials exclude elderly patients from participation. Co-morbidities and increased risk of neurotoxicity limit application of aggressive therapies like high-dose chemotherapy and whole brain radiation in this population. Clinical trials specifically for elderly PCNSL are limited and this represents an unmet medical need. A conference focused on this problem is of high priority for the IPCG." |